SOURCE: Benda Pharmaceutical, Inc.

February 12, 2007 09:25 ET

Benda Pharmaceutical, Inc. Appoints Eric Yu Tak Shing as Its Chief Financial Officer

HUBEI PROVINCE, CHINA -- (MARKET WIRE) -- February 12, 2007 -- Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a Chinese-based pharmaceutical company engaged in the development, manufacturing and distribution of medicines, active pharmaceutical ingredients and pharmaceutical intermediaries, announced today the appointment of Eric Yu Tak Shing as Chief Financial Officer effective February 9, 2007. Mr. Yu is a certified public account (CPA, Hong Kong and CPA, Australia) with 13 years of experience in public and corporate accounting and finance, most recently as Financial Controller of Beijing Teletron Telecom Engineering Co., Ltd. Mr. Yu began his career in 1993 with BDO Kwan Wong Tan & Fong, which was acquired by Deloitte Touche Tohmatus in 1996. He has held progressively more responsible positions with companies in China, Hong Kong, Australia and the United States, gaining in-depth knowledge and understanding of the accounting procedures, standards and issues in accordance with PRC GAAP, US GAAP and Hong Kong GAAP. Mr. Yu is fluent in English, Mandarin and Cantonese. He holds a Bachelor of Commerce Degree in Accountancy and Legal Studies from the University of Wollongong in Australia.

"Benda Pharmaceutical is deeply committed to fulfilling its corporate responsibilities as a U.S. public company," said Benda CEO, Yiqing Wan. "The appointment of Mr. Yu as Benda's Chief Financial Officer is an important milestone and one essential to that effort. His intimate knowledge of U.S. GAAP and the U.S. capital markets will help us develop the rigorous discipline in our corporate governance, financial reporting and investor communications that will be required on our path to eventually becoming a NASDAQ listed stock."

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. ( is engaged in the business of identifying, discovering, developing, and manufacturing conventional medicines, active pharmaceutical ingredients, bulk chemicals (or pharmaceutical intermediates), and Traditional Chinese Medicines ("TCMs") for the treatment of some of the most widespread common ailments and diseases (e.g. common cold, diabetes, and cancer).


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information